Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
5.20
+0.07 (1.36%)
At close: Feb 6, 2026, 4:00 PM EST
5.17
-0.03 (-0.58%)
After-hours: Feb 6, 2026, 7:35 PM EST
Niagen Bioscience Employees
Niagen Bioscience had 104 employees as of December 31, 2024. The number of employees decreased by 2 or -1.89% compared to the previous year.
Employees
104
Change (1Y)
-2
Growth (1Y)
-1.89%
Revenue / Employee
$1,199,125
Profits / Employee
$196,433
Market Cap
416.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 104 | -2 | -1.89% | 104 | 0 |
| Dec 31, 2023 | 106 | -7 | -6.19% | 106 | 0 |
| Dec 31, 2022 | 113 | -2 | -1.74% | 113 | 0 |
| Dec 31, 2021 | 115 | 5 | 4.55% | 115 | 0 |
| Dec 31, 2020 | 110 | 0 | - | 110 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsNAGE News
- 1 day ago - Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - Business Wire
- 23 days ago - Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - Business Wire
- 6 weeks ago - Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast - Business Wire
- 3 months ago - Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years - Seeking Alpha
- 3 months ago - Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside) - Business Wire
- 3 months ago - Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID - Business Wire
- 3 months ago - Niagen Bioscience Announces $10 Million Share Repurchase Program - Business Wire
- 3 months ago - Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript - Seeking Alpha